AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11552198
Drug: Calf muscles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf muscles stretching (control treatment)
Trial: 9972406
Drug: Liposomal encapsulated
RxNorm normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liposomal encapsulated doxorubicin (DOX‐SL) 20‐40mg/m2 administered by intravenous infusion over 30‐60 minutes every two weeks
Trial: 3130890
Drug: Atropine 1
RxNorm normalized name: homatropine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 1 mg
Trial: 14987305
Drug: Mequitazine 5
RxNorm normalized name: mequitazine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mequitazine 5 mg
Trial: 31018832
Drug: Aggregate treatment
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggregate treatment effect estimates
Trial: 20390429
Drug: Zibotentan (ZD4054)
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan (ZD4054) 10 mg or 15 mg
Trial: 12827121
Drug: Topical local
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical local anesthetic (adrenaline 1:1,000, lignocaine 4%, amethocaine 0.5%)
Trial: 12827121
Drug: Placebo (adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (adrenaline 1:1,000 solution)
Trial: 8894262
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 mg, doubled to 40 mg in nonresponders)
Trial: 8894262
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 mg, doubled to 200 mg in nonresponders)
Trial: 8894262
Drug: Quinapril (52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (52 weeks treatment in a volunteer group of 327 patients)
Trial: 8894262
Drug: Metoprolol (52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (52 weeks treatment in a volunteer group of 327 patients)
Trial: 30616662
Drug: MATCH (Modular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MATCH (Modular Approach to Therapy for children with Anxiety, Depression, Trauma and Conduct problems)
Trial: 22967497
Drug: Antazoline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antazoline administered intravenously in divided doses
Trial: 22967497
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously in divided doses
Trial: 19631852
Drug: Indirect pulp
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect pulp capping treatment; specific details on dosage and duration not available.
Trial: 28781129
Drug: IH oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IH oxytocin (all doses)
Trial: 23760428
Drug: Escitalopram (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (selective serotonin reuptake inhibitor)
Trial: 18053020
Drug: Triflusal (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (225 mg, 450 mg, 900 mg)
Trial: 12671885
Drug: Fructooligosaccharides (FOS)
RxNorm normalized name: fructooligosaccharides (FOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructooligosaccharides (FOS) 6.6 g, administered 3 times daily after meals
Trial: 10626715
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg epidural morphine bolus with continuous epidural infusion of 4 mg morphine in 100 ml bupivacaine 0.125% (Group 1)
Trial: 9174679
Drug: Ibuprofen effervescent
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen effervescent 400 mg
Trial: 9174679
Drug: Ibuprofen effervescent
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen effervescent 800 mg
Trial: 8645662
Drug: Ibuprofen tablets
RxNorm normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen tablets 400 mg
Trial: 9174679
Drug: Ibuprofen tablets
RxNorm normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen tablets 800 mg
Trial: 9174679
Drug: Ibuprofen effervescent
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen effervescent
Trial: 23682858
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (60-min exercise class twice a week for 3 months)
Trial: 19594035
Drug: Comprehensive rehabilitation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive rehabilitation therapy including joint range of motion, activities of daily living, and restoring muscle strength starting from the 2nd day after surgery.
Trial: 9661542
Drug: Warming intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming intravenous fluids at 42 degrees C
Trial: 7854554
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy according to IOR‐OS/NEO 3 protocol
Trial: 2574496
Drug: Atenolol (beta-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta-1 selective beta blocker)
Trial: 237423
Drug: AH 8165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH 8165 D (0.4-0.8 mg/kg body weight)
Trial: 27117972
Drug: Lutonix drug-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutonix drug-coated balloon (DCB)
Trial: 21932567
Drug: Beta-blocker metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker metoprolol tartrate
Trial: 21932567
Drug: Standard antianginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antianginal therapy (including nitrates, anticoagulants, ACE inhibitors, and statins)
Trial: 16169185
Drug: Intensive cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cognitive-behavioral group treatment (CBGT)
Trial: 8110914
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (mean serum level of 0.54 mEq/L)
Trial: 8110914
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment and Placebo treatment
Trial: 3606937
Drug: Dextropropoxyphene hydrochloride
RxNorm normalized name: Dextropropoxyphene hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene hydrochloride 65 mg 8 hourly
Trial: 3358901
Drug: Theophylline 125
RxNorm normalized name: theophylline 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 125 mg 8 hourly
Trial: 3606937
Drug: Tolbutamide 500
RxNorm normalized name: tolbutamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide 500 mg i.v.
Trial: 29866131
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) with co-intervention exercise strategies (spine mobilizing and multifidus activating)
Trial: 26254317
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment
Trial: 19014835
Drug: Bevirimat 200
RxNorm normalized name: Bevirimat
DrugBank: Bevirimat (DB06581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevirimat 200 mg/d for 14 days
Trial: 19014835
Drug: Atazanavir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 400 mg/d on days 1 through 21 and bevirimat 200 mg/d on days 8 through 21
Trial: 19014835
Drug: Atazanavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir monotherapy
Trial: 16172184
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (1 mg) after 100 mg fluconazole
Trial: 16172184
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (1 mg) after 200 mg fluconazole
Trial: 16172184
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (1 mg) after 400 mg fluconazole
Trial: 16172184
Drug: Intravenous alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfentanil (15 microg/kg) after 100 mg fluconazole
Trial: 16172184
Drug: Intravenous alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfentanil (15 microg/kg) after 200 mg fluconazole
Trial: 16172184
Drug: Intravenous alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfentanil (15 microg/kg) after 400 mg fluconazole
Trial: 16172184
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (3 mg) after 100 mg fluconazole
Trial: 16172184
Drug: Oral alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alfentanil (40 microg/kg) after 100 mg fluconazole
Trial: 8685201
Drug: Tianeptine 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine 37.5 mg/day
Trial: 6182817
Drug: Alloferin (alcuronium)
RxNorm normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alloferin (alcuronium) in burned patients, initial dose 23.75 mg (0.35 mg/kg)
Trial: 6182817
Drug: Alloferin (alcuronium)
RxNorm normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alloferin (alcuronium) in control group, initial dose 15 mg (0.21 mg/kg)
Trial: 31492121
Drug: Uitblinkers intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uitblinkers intervention (three sessions between an oral healthcare professional and parent)
Trial: 29267221
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g whey protein (120 kcal)
Trial: 29267221
Drug: 70 g
RxNorm normalized name: alcohol .70 g in 1 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 g whey protein (280 kcal)
Trial: 24359313
Drug: SPN-804 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-804 1200 mg
Trial: 24359313
Drug: SPN-804 2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-804 2400 mg
Trial: 19318138
Drug: Mifepristone (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (plasma levels > or =1800 ng/ml)
Trial: 15162890
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin every 24 hours (10 mg/kg/dose for patients aged 6 months to < 9 years, 8 mg/kg/dose for 9 to < 12 years, 6 mg/kg/dose for ≥ 12 years)
Trial: 15162890
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin every 8 hours (2.5 mg/kg/dose)
Trial: 15162890
Drug: Intravenous tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous tobramycin every 24 hours
Trial: 8762219
Drug: Nicardipine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 50 mg slow release form (n = 57)
Trial: 8762219
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg twice daily (n = 54)
Trial: 1756043
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 g single preoperative dose)
Trial: 7141761
Drug: Propranolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (5 mg i.v.)
Trial: 6124442
Drug: Labetalol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (20 mg i.v.)
Trial: 6124442
Drug: Practolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (10 mg i.v.)
Trial: 6124442
Drug: Labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (200 mg x 2, oral)
Trial: 29561483
Drug: Mixed conventional/piezosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed conventional/piezosurgery preparation
Trial: 29561483
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation with drills
Trial: 25011352
Drug: HDM SLIT-tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM SLIT-tablet (maximum dose 32 DU in adults, 12 DU in children), administered once daily for 28 days
Trial: 25011352
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered once daily for 28 days
Trial: 25011352
Drug: HDM SLIT-tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM SLIT-tablet (maximum dose 12 DU in children), administered once daily for 28 days
Trial: 20584227
Drug: Almotriptan 12.5
RxNorm normalized name: almotriptan 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan 12.5 mg administered within 1 h of pain onset and when pain was mild (early + mild intervention group)
Trial: 27829367
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg IV morphine
Trial: 15616079
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.5% bupivacaine infiltrated subcutaneously
Trial: 15616079
Drug: Inhaled 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 50% nitrous oxide in oxygen (Entonox) via a demand valve
Trial: 11851182
Drug: Intracutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injections of botulinum toxin (Botox) 2.5 U/0.1 ml, injected at 0.5 U/cm2 with 1 cm distance between injection points.
Trial: 10468682
Drug: Famotidine 80
RxNorm normalized name: ibuprofen/famotidine 800 mg-26.6 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 60)
Trial: 10468682
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 60)
Trial: 10468682
Drug: Famotidine 80
RxNorm normalized name: ibuprofen/famotidine 800 mg-26.6 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 52)
Trial: 10468682
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 57)
Trial: 8589025
Drug: Cisplatin 8
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 8 mg/m2 on days 1-2, 8-9, 15-16, 22-23 and 5-fluorouracil 300 mg/m2 on days 3-7, 10-14, 17-21, 24-28 (35-day courses)
Trial: 28973620
Drug: Genotype-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided warfarin dosing
Trial: 31259883
Drug: Traditional clinically
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional clinically guided warfarin dosing (Control)
Trial: 26754176
Drug: Ceftriaxone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone administered at home
Trial: 26754176
Drug: Flucloxacillin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flucloxacillin administered in hospital
Trial: 19470925
Drug: Paclitaxel (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (225 mg/m²) plus Carboplatin (AUC 6)
Trial: 11351919
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program implemented at CVS pharmacies
Trial: 9783644
Drug: HMG reductase
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG reductase inhibitors
Trial: 9783644
Drug: High-dose reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose reductase inhibitors
Trial: 3048574
Drug: Busulfan maintenance
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan maintenance plus pulsed doses of cytarabine and lomustine
Trial: 30086252
Drug: Standard dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dressing (povidone-iodine gauze and patch)
Trial: 10763397
Drug: 900-mL 75-g
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 900-mL 75-g OGTT
Trial: 10763397
Drug: 600-mL 75-g
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600-mL 75-g OGTT
Trial: 10763397
Drug: 300-mL 75-g
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300-mL 75-g OGTT
Trial: 9029414
Drug: Intravenous forskolin
RxNorm normalized name: Coleus forskohlii root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous forskolin (75 minute infusion)
Trial: 3317344
Drug: Recombinant vaccine
RxNorm normalized name: CHO Cells Recombinant Vaccine
DrugBank: CHO Cells Recombinant Vaccine (DB15893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant vaccine
Trial: 1450684
Drug: Plasma-derived vaccine
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived vaccine
Trial: 29880546
Drug: Repetitive CD34+
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive CD34+ cell therapy (group A)
Trial: 29880546
Drug: Single-dose CD34+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose CD34+ cell therapy (group B)
Trial: 25363186
Drug: omega-3 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 (1000 mg/day)
Trial: 15686271
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen Therapy (HBO2), 120 treatments in blocks of 80 and 40 with a five-month break
Trial: 11431192
Drug: Intraperitoneal cefepime,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cefepime, 1 g once daily (group A)
Trial: 11431192
Drug: Intravenous vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vancomycin and netilmicin at conventional doses (group B)
Trial: 29720238
Drug: 48 hours
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 hours of postoperative intravenously administered (IV) antibiotics
Trial: 29720238
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of postoperative IV antibiotics
Trial: 29720238
Drug: 48 hours
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 hours of postoperative IV antibiotics
Trial: 18608311
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural group therapy for a 10-week period with relevant homework activities
Trial: 12717068
Drug: Subdermal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdermal injection of both blue dye and radiotracer (Group A)
Trial: 12717068
Drug: Periareolar injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periareolar injection of blue dye and subdermal injection of radiotracer (Group B)
Trial: 1380024
Drug: Paracentesis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracentesis with Dextran 70 (6 g for each 1000 ml of ascites removed)
Trial: 1380024
Drug: Paracentesis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracentesis with albumin (6 g for each 1000 ml of ascites)
Trial: 6436832
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg sulfinpyrazone and 75 mg dipyridamole
Trial: 6436832
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ASA and 75 mg dipyridamole
Trial: 6436832
Drug: 330 mg
RxNorm normalized name: urea 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 330 mg ASA and 75 mg dipyridamole
Trial: 31619187
Drug: Daprodustat 10
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat 10 mg TIW
Trial: 31619187
Drug: Daprodustat 15
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat 15 mg TIW
Trial: 31619187
Drug: Daprodustat 25
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat 25 mg TIW
Trial: 31619187
Drug: Daprodustat 30
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat 30 mg TIW
Trial: 24824481
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) as an adjunct to usual care (12-18 sessions)
Trial: 24824481
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) as an adjunct to usual care
Trial: 20022344
Drug: Cortisol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (160 mg/d for 4 days)
Trial: 16226134
Drug: Prednisolone 50
RxNorm normalized name: prednisolone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 50 mg twice a day